promo_leaderboard Ad
‹ All stocks
TNGX

Tango Therapeutics

TNGX · NASDAQ · Healthcare
$23.51
▼ $0.66 (-2.73%)
$20.87 $23.22 $25.58 $27.93 $23.51 Sep 2026 Oct 2026 Nov 2026
Day range
$23.34 – $24.32
Year range
$7.69 – $34.39
Open
$24.08
Previous close
$24.17
Market cap
$3.98B
Volume (24h)
$85.3K
Volume (52w)
$2.01M
Performance
7D
▼ -3.25%
1M
▼ -0.08%
3M
▼ -6.71%
6M
▲ 8.74%
1Y
▲ 194.61%
YTD
▲ 163.27%
3Y
▲ 208.94%
5Y
▲ 98.06%
All-time
▲ 129.81%
Key statistics
P/E ratio
-17.16
EPS (TTM)
$-1.37
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
169.5M
About Tango Therapeutics

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

Visit website
Country: United States of America
Related news
More in Healthcare